Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1041 to 1050 of 2733 total matches.
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.1
Pronunciation Key
Fluticasone ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.
Erenumab (Aimovig) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
preventive treatment.1,2
Beta blockers and antiepileptic drugs are commonly
used for prevention of migraine ...
The FDA has approved erenumab-aooe (Aimovig –
Amgen/Novartis), a once-monthly, subcutaneously-injected,
monoclonal antibody against the calcitonin
gene-related peptide receptor, for preventive treatment
of migraine in adults. It is the first drug in its class to
be approved by the FDA.
A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
old.1
Pronunciation Key
Symbravo: sim brah’ voh
STANDARD TREATMENT — Treatment of migraine pain ...
The FDA has approved Symbravo (Axsome), an oral
fixed-dose combination of the nonsteroidal anti-inflammatory
drug (NSAID) meloxicam and the
5-HT1B/1D receptor agonist (triptan) rizatriptan (Maxalt,
and generics), for acute treatment of migraine with or
without aura in adults. It is the second combination
of an NSAID and a triptan to be approved for migraine
treatment. An oral fixed-dose combination of
sumatriptan and naproxen (Treximet, and generics) is
approved for use in patients ≥12 years old.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):68-70 doi:10.58347/tml.2025.1727b | Show Introduction Hide Introduction
Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
The Medical Letter on Drugs and Therapeutics • Sep 15, 2025 (Issue 1737)
infections (ABSSSIs),
and community-acquired bacterial pneumonia (CABP)
(see Table 1). It is the second ...
Ceftobiprole medocaril sodium (Zevtera – Innoviva
Specialty Therapeutics), a new IV cephalosporin
antibacterial drug, has been approved by the FDA for
treatment of Staphylococcus aureus bacteremia (SAB),
including right-sided infective endocarditis, acute
bacterial skin and skin structure infections (ABSSSIs),
and community-acquired bacterial pneumonia (CABP)
(see Table 1). It is the second cephalosporin with
activity against methicillin-resistant S. aureus (MRSA)
to be approved in the US; ceftaroline (Teflaro), which
was approved for treatment of ABSSSIs and CABP in
2010, was the...
Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-52 doi:10.58347/tml.2025.1737d | Show Introduction Hide Introduction
Tegaserod Maleate (Zelnorm) for IBS with Constipation
The Medical Letter on Drugs and Therapeutics • Sep 16, 2002 (Issue 1139)
and widely distributed. Plasma concentrations peak about 1 hour after ingestion, but taking the drug ...
Tegaserod maleate (teg a ser' od; Zelnorm - Novartis), a serotonin derivative, has received FDA approval for short-term treatment of women with irritable bowel syndrome (IBS) whose primary symptom is constipation. Alosetron (Lotronex), which was withdrawn previously because of toxicity, will soon be available again for women with severe diarrhea-predominant IBS (Medical Letter 2002; 44:67).
Augmentin XR
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003 (Issue 1148)
Amoxicillin 500 — 1 tab q8h 1500
Amoxil, and others 875 — 1 tab q12h 1750
Amoxicillin/clavulanic acid ...
Augmentin XR (GlaxoSmithKline), an oral extended-release combination of amoxicillin and the beta-lactamase inhibitor clavulanic acid, is now being promoted for treatment of acute bacterial sinusitis and community-acquired pneumonia. Augmentin XR contains a higher dose of amoxicillin than Augmentin.
Brivaracetam (Briviact) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016 (Issue 1499)
approved initially only as adjunctive
treatment for partial seizures.1
Pronunciation Key
Brivaracetam ...
Brivaracetam (Briviact – UCB), an analog of
levetiracetam (Keppra, and others), has been approved
by the FDA for adjunctive treatment of partial-onset
seizures in patients ≥16 years old. New drugs for
epilepsy are often approved initially only as adjunctive
treatment for partial seizures.
Prasterone (Intrarosa) for Dyspareunia
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
, cardiovascular,
and neuropsychiatric dysfunction.1-3
Table 1. Pharmacology
Class Steroid
Formulation 6.5-mg ...
The FDA has approved the steroid prasterone
(Intrarosa – Endoceutics) for intravaginal treatment
of postmenopausal women with moderate-to-severe
dyspareunia due to vulvovaginal atrophy (VVA). Also
called dehydroepiandrosterone (DHEA), prasterone
is produced in the adrenal glands, gonads, and brain
and converted intracellularly into active metabolites
of estrogens and androgens. DHEA has been available
over the counter for years as an oral dietary supplement
claimed to benefit sexual, cardiovascular, and
neuropsychiatric dysfunction.
Fitusiran (Qfitlia) for Hemophilia A and B
The Medical Letter on Drugs and Therapeutics • Jul 07, 2025 (Issue 1732)
disorder (estimated prevalence 1:5000 live
male births) characterized by insufficient levels ...
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected,
antithrombin-directed, small interfering ribonucleic
acid (siRNA), has been approved by the FDA for routine
prophylaxis to prevent or reduce the frequency of
bleeding episodes in patients ≥12 years old who have
hemophilia A with or without factor VIII inhibitors or
hemophilia B with or without factor IX inhibitors. It
is the first antithrombin-lowering therapy to become
available in the US for treatment of hemophilia.
Med Lett Drugs Ther. 2025 Jul 7;67(1732):110-1 doi:10.58347/tml.2025.1732c | Show Introduction Hide Introduction
Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025 (Issue 1743)
hrs
2-4 hrs
2-4 hrs
1.5-6.5 hrs
2-12 hrs
14-24 hrs
14-24 hrs
14-24 hrs
18-24 hrs
12 ...
View the Comparison Chart: Some Available Insulins for Type 2 Diabetes
Med Lett Drugs Ther. 2025 Dec 8;67(1743):e201-4 doi:10.58347/tml.2025.1743d | Show Introduction Hide Introduction
